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A B S T R A C T
A panel of experts was convened by the International Society for Infectious Diseases (ISID) to overview
recommendations on managing and preventing vascular catheter infections, specifically for the
prevention and management of central line-associated bloodstream infections. These recommendations
are intended to provide insight for healthcare professionals regarding the prevention of infection in the
placement and maintenance of the catheter and diagnosis as well as treatment of catheter infection.
Aspects of this area in pediatrics and in limited-resource situations and a discussion regarding the
selection of empiric or targeted antimicrobial therapy are particular strengths of this position paper.
© 2019 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Central lines are essential vascular access devices used in
critically-ill patients in many medical settings. Central line-
associated bloodstream infections (CLABSIs) are commonciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
niversity from ClinicalKey.com by Elsevier on October 21, 
ission. Copyright ©2021. Elsevier Inc. All rights reserved.
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hospital-acquired bacteremias/fungemias occurring with a vascu-
lar access device (Crnich and Maki, 2001). CLABSIs substantially
increase morbidity, mortality, length of hospital stay, and
increased hospital costs, both in developed and resource-limited
countries (Al-Abdely et al., 2017; Devrim et al., 2016; Ziegler et al.,
2014; Tarricone et al., 2010; Higuera et al., 2007; Rosenthal et al.,
2003). The CLABSI rates in resource-limited countries are 3–5
times higher than that encountered in high-income settings (Al-
Abdely et al., 2017) and 75% of the world’s population live in low-
to-middle income countries (LMICs) (Alp and Rello, 2019).
Established in 1998, the International Nosocomial Infection
Control Consortium (INICC) is one group which has used
surveillance and applied research to promote appropriate practices
to decrease this rate (Rosenthal, 2016). This paper summarizes the
key recommendations for CLABSI control and prevention by the
International Society for Infectious Diseases.
Known facts - prevention
Many guidelines for decreasing CLABSI rates recommend use of
“care bundles” (Marwick and Davey, 2009; Agency for Healthcare
Research and Quality, 2018), to simplify and enable the reliable
application of 4–6 evidence-based best practices simultaneously,
to achieve better outcomes than when implemented individually.
Care bundles for device-associated infections e.g. CLABSI bundles,
are widely-adopted and effective infection prevention strategies in
high-income countries and some low-resource settings.
Compliance with bundle elements should be easily and
objectively measureable (e.g. ‘yes/no’ or ‘completed/not complet-
ed’), allowing for tracking of bundle compliance rates. Infection rate
trends can be followed using run-charts. CLABSI bundles have been
created for both the insertion and maintenance of central lines. Many
CLABSI events are attributed to breaches in catheter maintenance,
rather than insertion which, because it remains longer in situ than a
peripheral line, accounts for most of the cases of intravascular
catheter bacteremia. These bundles are summarized here (Ling et al.
2016; Bell and O’Grady, 2017; Han et al., 2010):
Insertion bundle
1. Site/Catheter Selection
Optimal site selection will depend on catheter types and
expected duration of use with avoidance of placement in the
femoral vein, except for hemodialysis and in some pediatric
patients. The type of device and placement site selection are
influenced by the training and experience levels of the clinician
inserting the device. Ultrasound guidance should be used when
available. The hub number on the catheter should be kept to the
minimum essential for management, as every additional hub
increases the risk for CLABSI development. All components of the
system should be compatible to minimize leakages. For needleless
systems, a split septum valve may be preferable to a mechanical
valve.
Peripherally inserted central catheters (PICC lines) seem more
vulnerable to thrombosis and dislodgement than central venous
catheters placed in the internal jugular or subclavian veins.
Importantly, in patients with renal injury who may require
hemodialysis, preservation of upper extremity veins for future
dialysis access is advisable so use of PICC lines needs to be prudent
in these patients.
The use of a midline catheter (placed in proximal veins such as
the brachial or cephalic with the tip in the axillary vein) is
associated with a lower complication risk of pneumothorax and
thrombosis and lower CLABSI rates in some reports.Downloaded for Anonymous User (n/a) at Stellenbosch Univer
2021. For personal use only. No other uses without permission1. Hand Hygiene
Hand hygiene is vital before and after palpating the insertion
site and before and after all interactions in the placement and
maintenance sequences. Hand hygiene can be performed with an
alcohol-based hand rub or antiseptic soap with water. Optimal
asepsis dictates the use of sterile gloves with placement. The
wearing of gloves does not obviate the need for hand hygiene.
1. Skin Preparation
Skin prep is generally done with the use of a 0.5–2%
chlorhexidine/70% isopropyl alcohol solution, with alternatives
such as iodophors (povidone-iodine) or alcohol alone in patients
with known hypersensitivity to chlorhexidine gluconate. The
antiseptic should be allowed to dry before catheter insertion.
1. Barrier Precautions
Barrier precautions include the use of sterile gowns and gloves,
a surgical mask and cap/hair net as well as a full body sterile drape
over the patient (akin to drapes utilized in an operating theater).
All aspects of the insertion bundle are likely essential in
preventing CLABSIs. Insertion in the femoral area, not using a full
body drape, not using all components of the maximal sterile
barrier precautions and not performing all components of the
bundle, have been identified as factors associated with an
increased risk of CLABSI (Lee et al., 2018).
Catheter maintenance bundle
1. Review of Need and Replacement
The need for the line should be reviewed daily since risk of
CLABSI development increases over time. If the catheter was
placed as an emergency intervention, it should be replaced as soon
as possible. Fever alone is not an indication for catheter removal
and replacement. However, if CLABSI is clinically suspected in a
non-tunneled device, the device should not simply be replaced
over a guidewire, but removed, with a new catheter inserted at a
different site.
1. Hand Hygiene
This should be performed before and after accessing, repairing
or dressing the catheter to maintain aseptic technique at all times.
This includes wearing sterile or at least clean gloves when
changing dressings.
1. Hub/Access Device Disinfection
Catheter hubs, connectors, and injection ports should be
disinfected with alcoholic chlorhexidine, 70% alcohol solution or
an iodophor while applying mechanical friction before access. All
needleless parts of the system should be changed when the
administration set is changed or based on manufacturers’
recommendations. There is no benefit in changing more often
than 72 h. Access ports should be treated with an antiseptic prior to
any access (Marschall et al., 2014). Disinfectant cap protectors may
also have a role but require further study (Jimenez et al., 2015).
1. Dressing Changes
A sterile transparent and semipermeable dressing is preferred
over sterile gauze. Sterile gauze can be used if the patient is
diaphoretic or the site is actively bleeding or oozing. The dressingsity from ClinicalKey.com by Elsevier on October 21, 
. Copyright ©2021. Elsevier Inc. All rights reserved.
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every 7 days for non-tunneled catheters (Marschall et al., 2014).
The use of a chlorhexidine-impregnated dressing, if available, may
decrease the risk of infection as compared to non-impregnated
dressings, through reduction of bacterial colonization of the skin at
the point of catheter insertion. In settings with high CLABSI rates,
chlorhexidine-impregnated sponge dressings may be used as an
additional intervention.
Topical antimicrobial ointments or creams are generally not
used except for hemo-dialysis catheters where they may have a
role in minimization of fungal infections and antimicrobial
resistant infections.
Patients should be encouraged to report any changes to the
catheter insertion site or any discomfort as soon as possible.
Additional Measures (mainly in case of sustained high CLABSI
rates or during an outbreak):
1. Daily chlorhexidine bathing has been demonstrated to reduce
CLABSI rates among adult and children in intensive care units
(Frost et al., 2016; Dicks et al., 2016). Huang et al. (2019), despite
a lack of overall protective effect in non-ICU patients, found
reductions in MRSA and VRE infections in patients with medical
devices.
2. Antibacterial impregnated catheters (minocycline/rifampin or
chlorhexidine/silver sulfadiazine) can be used as an additional
intervention in units with high CLABSI rates or in patients where
a prolonged catheter dwell time is anticipated.
3. A prophylactic antimicrobial (e.g. vancomycin) or antiseptic lock
solution (e.g. ethanol or taurolidine-citrate) can be considered
in patients with long-term catheters (such as hemodialysis) or
in patients with a history of recurrent CLABSI.
Variability in application of CLABSI prevention bundles,
compliance assessment and degree of stakeholder involvement,
all likely result in suboptimal clinical outcomes. Such variability
may explain issues related to suboptimal clinical impact of the
guidelines and their implementation (Blanco-Mavillard et al.,
2018).
Open vs closed intravenous infusion systems
The impact of the infusion system on CLABSI rates has been
studied by comparing open and closed intravenous systems. It has
been widely accepted that open systems may increase the risk of
contamination and administration-related CLABSI, because of
microbial entry into the system through air entry (Maki et al.,
2011). As reported in a recent systematic review (Perin et al., 2016),
by way of illustration, the rate of CLABSI was 35.3% greater among
patients who received compounded parenteral nutrition (PN)
through an open system in comparison to those who received PN
through a closed system.
In a randomized clinical trial comparing rates of CLABSI
between patients using an open system (three-way stopcocks)
and standard flushing, and patients using a closed system (pre-
pierced septa) and single-use prefilled flushing devices, it was
shown that closed systems had significantly lower rates of CLABSI
(2.21 per 1000 CL-days vs. 6.40 per 1000 CL-days, 95% CI 0.16-0.76,
p = 0.006) and was cost-effective (Rosenthal et al., 2015). However,
open infusion containers and systems, such as three-way stop-
cocks, continue to be widely used in limited-resource settings.
Management of the CLABSI (suggested practice)
In a patient with a suspected CLABSI, the healthcare profes-
sional is usually presented with a febrile individual without focal
signs or symptoms suggesting systemic or device-associatedDownloaded for Anonymous User (n/a) at Stellenbosch Uni
2021. For personal use only. No other uses without permisinfection. In the case of Staphylococcus aureus (S. aureus) infection
(either methicillin sensitive or resistant), secondary metastatic
infection can be found in any organ. Fever without a focus is a clue
that should prompt investigation for CLABSI. Blood cultures should
be obtained in parallel from the central line and from a peripheral
site. A shorter time to positivity (or a higher bacterial load on
quantitative blood cultures) from the central source can be a hint
that the line is the primary source but it is not particularly sensitive
(Bouzidi et al., 2018).
The most common organisms causing CLABSI are biofilm-
producing Gram positive cocci including S. aureus and coagulase
negative staphylococci (CNS). Most CNS-associated CLABSI events
present with a milder or more indolent course, however S.
lugdunensis infections manifest with more prominent symptom-
atology, behaving clinically similar to S. aureus-associated CLABSI.
While cultures are pending, vancomycin is an appropriate
antimicrobial to use empirically until identification and antimi-
crobial sensitivities are available. In countries without high rates of
MRSA, an anti-staphylococcal beta-lactam antimicrobial could be
the first option. However, in severe illness, neutropenic or
otherwise immunocompromised patients and those with a
femoral catheter, additional empiric coverage for Gram-negative
bacilli is reasonable. Agents such as an extended spectrum
penicillin (such as piperacillin/tazobactam), a cephalosporin (such
as cefepime) or a carbapenem (such as meropenem) may be
appropriate, based on prevailing institutional antimicrobial resis-
tance patterns. Other organisms associated with CLABSIs include
fungi (yeasts), especially Candida species including the more
resistant C. auris, and some of the more indolent Gram-positive
organisms such as “diphtheroids”, primarily Corynebacterium
species and Cutibacterium (formerly Propionibacterium) acnes.
The decision to begin antimicrobials before cultures are positive
should be based on clinical judgement and illness severity. Fever in
a patient with a central vascular catheter does not necessarily
mean that the etiology of the pyrexia is a CLABSI. Numerous other
diagnoses, infectious or non-infectious, may be the source of the
fever. Absence of fever does not rule out CLABSI, or any other
infection for that matter, as especially in debilitated, elderly or
with renal injury, a febrile response may not occur. When blood
cultures are positive without another identified source for a likely
organism, CLABSI is likely the diagnosis. Catheters are often not
removed prior to laboratory-confirmation of CLABSI, unless the
catheter is no longer required.
Once the blood cultures are positive, especially in the absence of
an identified focus, all peripheral venous or arterial catheters,
midline catheters and short term nontunneled central venous
catheter should ideally be removed (Han et al., 2010). In the case of
long-term catheters such as PICC lines, tunneled central lines and
implantable devices, explantation is done in most instances. The
approach to removal of a central catheter in a patient with
bacteremia and a clear alternative focus should be individualized
based on the organism and clinical circumstances. Antimicrobial
locks as a catheter salvage strategy are unlikely to be effective but
may be considered under certain conditions for salvage (Mermel
et al., 2009). Certainly, any persistent bacteremia despite
appropriate antimicrobials should be managed with antimicro-
bials and prompt catheter removal.
The length of antimicrobial therapy after catheter removal is
often 7–14 days but varies with the pathogen (longer for Gram-
negative and fungal infections) and the degree of illness. Some
microbes are more likely to cause secondary metastatic infections,
especially S. aureus, and the clinician should be aware of this
possibility. Certainly, if a cardiac valve infection (endocarditis) or a
bone infection (osteomyelitis) develops as a secondary manifesta-
tion of the CLABSI, more prolonged antimicrobial therapy (4–6
weeks) is required. Classically, endocarditis and osteomyelitis haveversity from ClinicalKey.com by Elsevier on October 21, 
sion. Copyright ©2021. Elsevier Inc. All rights reserved.
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recent data suggests that oral treatment can substitute for some of
the course (Iversen et al., 2019; Li et al., 2019) in defined patient
groups. This approach, as it becomes more validated (Boucher,
2019) will, like effective antimicrobial stewardship programs that
facilitate intravenous to oral therapy switches, decrease the time
that the central line is present and therefore will decrease the risk
of CLABSI.
CLABSIs in pediatrics
CLABSI rates in children and neonates are a challenge and have
been reported to be higher than in the adults (The Joint
Commission, 2016; Leighton et al., 2012). In a review, neonatal
intensive care unit (NICU) CLABSI rates ranged from 2.6 to 60 cases
per 1000 central line days in limited-resource countries in
comparison with 2.9 cases per 1000 central line days in the USA
(Rosenthal, 2009). As a host, the newborn infant, and especially
premature newborn, is more susceptible to bloodstream infections
(BSIs) because of poor skin integrity and an immature immune
system. Their care usually involves A long hospital stay with
repeated invasive procedures, exposure to many caregivers, and
being in an environment prone to microbial colonization. Neonatal
outcomes have been affected by health care-associated infections
including CLABSIs. Indeed, the risk of neurodevelopmental
impairment especially in very low birthweight infants significantly
increases with one or more episodes of infection (Stoll et al., 2004).
The mortality related to bloodstream infections has been reported
to be 21%. In neonates, they lead to increase in length of stay by 23Table 1
Neonatal CLABSI Recommended Preventive Measures.
Category Suggested intervention
Administrative  Providing hand hygiene facilities in the u
 Provide CVL insertion and maintenance k
 Increase staff/patient ratio
 Dedicated central line team
 Training and monitoring staff competency
 Continuous monitoring of CLABSIs as qua
 Case root analysis for CLABSI events
Policies and Guidelines  CVL necessity, insertion, removal and dail
 Guidelines for the enteral and parental fe
fluid and medication)
 Antimicrobial stewardship
Risk Assessment based intervention  Assess for prematurity, intraabdominal pa
 Colonization and/or infection with multid
Implement Standard Infection
Prevention Techniques
 Perform hand hygiene with an approved a
catheter or changing the dressing
 Maintain aseptic technique during cathete
‘scrub the hub’
 Non-sterile gloves for routine handling of
Skin prep for neonates  Age less than 2 months : use povidone –i
 Age more than 2 months: use 2% chlorhe
Site selection  For catheter insertion in children the upp
Dwell time  No cut-off duration beyond which PICC sh
 Early UVC removal and replacement by P
Other risk reduction measures  Antimicrobial PICCs may reduce CLABSI, e
 Heparin in TPN (0.5 Units/mL)
 Fluconazole prophylaxis for babies <1000
 Minimize the use of H2 receptor blocker 
 Minimize the use of broad-spectrum anti
(UVC)Umbilical venous catheter, (PICC) Peripherally inserted central catheter, (VLBW) 
(Bizzarro et al., 2010; Pronovost, 2008; Mimoz et al., 2007; Garland et al., 2008; Birch et 
Kramer et al., 2017; Rosenthal et al., 2010.
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et al., 2014; Payne et al., 2018).
Unlike in the adult ICU, implementations of care bundles in
pediatric and neonatal intensive care units have had inconsistent
outcomes in reducing CLABSIs (Wirtschafter et al., 2010).
Additionally, studies in neonates have failed to demonstrate a
significant difference in CLABSI risk between catheter types used
mostly in the NICU (peripherally inserted, umbilical and femoral)
(Dubbink-Verheij et al., 2017). Studies have also shown that it is
possible to reduce neonatal CLABSI rates with hospital-based
interventions (Bizzarro et al., 2010; Pronovost, 2008). A recent
meta-analysis which included observational and case control
studies from different settings but no randomized control trails has
revealed a statistically significant reduction in CLABSIs rate (by
60%) following the introduction of care bundles (rate ratio = 0.40
(CI 0.31 to 0.51), p < 0.00001) although it is not clear which bundle
elements are effective in specific settings (Wirtschafter et al.,
2010). Some of the evidence-based interventions to reduce
CLABSIs in pediatric and neonatal units are summarized in Table 1.
Limited-Resource settings
A 2016 report of responses from 95 both high and middle
incomes countries showed a poor adherence to CLABSI prevention
guidelines is a universal observation (Valencia et al., 2016). In
resource-rich countries, risk reduction bundles are more readily
accepted and implemented, with proven efficacy in CLABSI rate
reduction. In resource limited settings, however, the CLABSI bundle
uptake, implementation, and program sustainability are majornit and monitor complains
its
 in infection control practices and line insertion and maintenance skills.
lity indicator with periodic feedback
y line care checklists
eding of VLBW infants (support breast feeding, duration of TPN and intravenous
thology, mucosal barrier injury, invasive procedures
rug resistant pathogen
lcohol-based product or antiseptic-containing soap before and after accessing a
r insertion, changing intravenous tubing and when entering the catheter including
 babies <1000 g
odine with 2 minutes dry time
xidine gluconate/70% isopropyl alcohol scrub
er or lower extremities (or the scalp in neonates or young infants) can be used
ould be removed electively.
ICC before day 4 might be considered
specially in high-risk subgroups
 g
and proton pump inhibitor
microbials
very low birth weight, (CVL) Central Venous line.
al., 2010; Cleminson et al., 2015; Puopolo and Escobar, 2014; Sanderson et al., 2017;
sity from ClinicalKey.com by Elsevier on October 21, 
. Copyright ©2021. Elsevier Inc. All rights reserved.
Table 2
Barriers, Challenges and Considerations for CLABSI Risk Reduction in Low and Middle Income Countries.
Measures to reduce CLABSI risk Barriers/Challenges Considerations/ Solutions
Establishing Surveillance
system to reduction targets
and identify areas of priority
 Complex case definitions
 Limited laboratory capacities
 Training of lab staff
 Introduction of lab quality systems
Staff shortages/
Inadequate number of skilled personnel for data management
 Use of cheap technology (Smart phone-based tools/prepro-
gramed data analysis systems)




Inadequate number of skilled personnel
 Support from management
 Unit-based quality nurse to follow up
 Assigning multispecialty intervention team
 Ongoing in-service training for all staff involved
High patient turnover/ Overcrowding  Tailored interventions
Limited resources
(infrastructure, technology, medical supplies
 Checklists
 Audit and feedback
Poor adherence to guidelines/Lack of written guidelines  Relentless focus on education, process and outcomes feedback
 Local training resources (e.g. peer tutoring)
 Online training resources
(Geldenhuys et al, 2017; Assis et al., 2018; Ider et al., 2012; The Joint Commission, 2012).
26 L. Lutwick et al. / International Journal of Infectious Diseases 84 (2019) 22–29barriers to wider adoption of this best practice intervention
(Table 2). Indeed, in a 2019 report, 5 of 16 sites (27%) in middle-
income countries reported no CLABSI prevention bundle use (Alp
et al., 2019).
The challenges to reduce CLABSI in LMICs start with the
surveillance, which is required to measure the baseline rates,
identify priority hospital areas to direct the limited resources, and
evaluate the effect of the intervention over time. Challenges
include complex case definitions that depend on laboratory criteria
for case confirmation, where many of these settings lack laboratory
microbiological capacities for standard pathogen identification, in
addition to the common clinical practices to obtain single drawing
of blood for culture (i.e. solitary blood culture) to save resources,
which minimize the amount of drawn blood leading to lower
chances to yield the BSI pathogen (Lamy et al., 2016) and also do
not allow for estimation of differential time to positivity of blood
cultures. As a result, inaccurate rates of BSIs are usually reported.
Training of laboratory staff and enforcing lab quality systems in
addition to inclusion of clinically based definitions (e.g. the clinical
sepsis) have been shown to improve the surveillance sensitivity,
and support establishing surveillance programs (See et al., 2013;
Talaat et al., 2016).
Another challenge is the availability of skilled staff and resources
for data collection and analysis for baseline numbers in assessing
infection prevention. For that, cheap technology such as smart
phones-based data collection tools, and preprogrammed analysis
and reporting tools can be developed to generate automatedTable 3
Intervention Results Using INICC Multidimensional Approach.
Country Pre-Intervention
Rate/1000 central line days
Post-Inte
Rate/100
Argentina 46.63 11.10 
Colombia 12.9 3.9 
Mexico 46.3 19.5 
Turkey 22.7 12.0 
India 6.4 3.9 
Saudi Arabia 6.9 3.1 
15 countries 14.7 9.7 




Argentina (ICU) 9.6 4.1 
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use online platforms for facilitated standardized data collection,
entry, and analysis, as the INICC Surveillance Online System (ISOS)
(Rosenthal, 2016). Additionally, surveillance approaches can be
selected to match the limited human resources, as settings may
choose to implement short-time, hospital-wide surveillance ap-
proach (e.g. repeatedpointprevalence surveys) to stratify the burden
of BSI among hospital departments (Ben Ayed et al., 2019), whereas
other settings utilize their limited resources for surveillance in high
risk areas as the ICUs (Rosenthal et al., 2016) (Table 3).
During implementation of the preventive measures, limitations
of human resources affect also the compliance with the prevention
guidelines, as shown by a study in Jordan where the nurse to
patient ratio of 1:1 was the only predictor of higher compliance
with the guidelines (Aloush and Alsaraieh, 2018). Effective
strategies may be used to overcome this challenge during
interventions, including assigning a nurse as a unit-based quality
nurse (Thom et al., 2014), or assembly of an intervention team of
physician, infection control nurse, and ICU nurse to assess and
follow up CLABSI cases (Hussain et al., 2017).
Prevention efforts should be focused on maximal aseptic
insertion of catheters, hand hygiene and adequate dressing
changes.
As highlighted by Rosenthal (2009), high CLABSI rates suggest
that LMICs face significant barriers for CLABSI reduction including
resources, appropriate medical supplies and adequate numbers of
skilled personnel. Additional examples include inadequate andrvention
0 central line days
% Decrease Reference
76% Rosenthal et al., 2003
73% Alvarez-Moreno et al., 2016
58% Higuera et al., 2005
47% Leblebicioglu et al., 2013
39% Jaggi et al., 2013
55% Al-Abdely et al., 2017
34% Rosenthal et al., 2010
51% Rosenthal et al., 2012
55% Rosenthal et al., 2013
57% Rosenthal et al., 2018
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dose vials used multiple times covered with contaminated tape,
cotton balls impregnated with contaminated antiseptic solutions
and semi-rigid plastic containers used for intravenous infusate
preparation. Furthermore, general infection prevention gaps and
breaches may contribute to high CLABSI rates e.g. lack of supplies
such as barrier protections and antiseptics, lack of sinks for hand
washing or access to alcohol based handrub, overcrowded
surroundings and untrained personnel.
Implementation of central-line bundles has the potential to
reduce the incidence of CLABSIs, as shown in a recent systematic
review and meta-analysis (Ista et al., 2016). It is noteworthy that
sustainable compliance with bundles involves the entire infection
control team, and a change in their habits may be necessary, as well
as continuous institutional support, updated educational inter-
ventions, and CLABSI surveillance data to improve patient care
practices. In other words, to achieve steady, high levels of
compliance with bundle elements, it is not sufficient to implement
it as one measure, but rather within a multidimensional infection
control approach.
INICC developed the INICC Multidimensional Approach,
which is implemented through a Surveillance Online System
(ISOS) software application, which includes: (1) a CLABSI
prevention bundle, (2) education, (3) outcome surveillance (4)
process surveillance, (5) feedback on CLABSI rates and con-
sequences, and (6) performance feedback of process surveil-
lance. As shown in the literature for developing countries and
limited-resource hospital settings, the rate of CLABSI has been
successfully reduced through the implementation of such
multidimensional programs, which include insertion and main-
tenance bundles for the prevention of CLABSIs in critically ill
patients of all ages, but also other interventions simultaneously
(Rosenthal et al., 2010).
Effective interventions with the INICC multidimensional
approach and ISOS were reported in ICUs from Argentina (46.63
vs. 11.10 CLABSIs per 1000 CL-days), showing a 76% reduction, and
57% reduction (incidence density rate: 0.43; 95% confidence
interval, 0.34-0.6; P < .001) (Rosenthal et al., 2003); Colombia,
showing a 73% CLABSI rate reduction (relative risk, 0.27; 95%
confidence interval, 0.14-0.52; P = .002) (Alvarez-Moreno et al.,
2016); Mexico (46.3 vs. 19.5 BSIs per 1000 IVD days) showing a 58%
reduction (Higuera et al., 2005); Turkey (22.7 to 12.0 CLABSIs per
1000 CL-days), showing a 47% reduction (Leblebicioglu et al.,
2013); India (6.4 CLABSIs to 3.9 CLABSIs per 1000 CL-days),
showing a 39% reduction (Jaggi et al., 2013); and Saudi Arabia (6.9
to 3.1 per 1000 CL-days) (Al-Abdely et al., 2017). In multicentric
studies conducted in adult ICUs (14.5 vs. 9.7 CLABSIs per 1000 CL-
days) from 15 countries (Argentina, Turkey, Colombia, India,
Mexico, Philippines, Brazil, Peru, El Salvador, Costa Rica, Cuba,
Lebanon, Macedonia, Morocco, and Panama), showed a 33%
reduction (Rosenthal et al., 2010); in pediatric ICUs from 5
countries (Colombia, India, Mexico, Philippines, and Turkey)(10.7
vs. 5.2 CLABSIs per 1000 CL-days), showed a 51% reduction
(Rosenthal et al., 2012), and in NICUs from 4 countries (El Salvador,
Mexico, Philippines, and Tunisia) showed a CLABSI rate decrease by
55%, from 21.4 per 1000 CL-days during phase 1 to 9.7 per 1000 CL-
days during phase 2 (rate ratio, 0.45 [95% confidence interval, 0.33-
0.63]) (Rosenthal et al., 2013).
In addition to the successful model of the INICC, other strategies
showed significant impact in increasing staff compliance, and
reduction of infection rates. Successful strategies included training
and education of the staff through formal sessions of presentations
and poster materials (Sahni et al., 2017), peer tutoring where
nurses and staff share in preparing and provision of the educative
materials (Park et al., 2017), or online provision of educative
materials (Hassan, 2018).Downloaded for Anonymous User (n/a) at Stellenbosch Univers
2021. For personal use only. No other uses without permissionFinally, as underscored by Alp and Rello (2019), implementation
of these prevention techniques can be quite challenging. As
presented by Alves et al. (2018), a “4E” approach can be useful:
Engagement of staff with a multi-disciplinary group with
involvement of local champions and using peer networks;
Education with materials and sessions;
Execution with standard care processes with redundancy;
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